本帖最后由 老马 于 2012-1-13 21:20 编辑
- |& |0 j! `% g6 [4 Q5 \% R$ w# M! G8 }4 Q y0 J" z
爱必妥和阿瓦斯丁的比较
' t+ }, Q% s6 H3 _1 N9 L) g# b
( X1 t7 A- U3 ~9 G C# s s2 U
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
; e, I) s7 A2 ?- p
% b2 V# z7 ^ U; J9 F
# R! i b/ }; J% g% D+ Y2 \* T
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/1 [- E2 B, K/ z1 `& G- N8 a
==================================================# G* a* w3 K5 ?* j; S) K" H4 g
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)* k5 O+ S: K- T. d7 L, n" d
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
% D5 ?8 k+ ~4 f% t; b+ w! AResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported., `! T, E7 Q7 T
|